DOAJ Open Access 2026

Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting

Bin Xue Yifan Liu Aibin Liang Wenjun Zhang

Abstrak

Abstract The field of chimeric antigen receptor (CAR)-T cell therapy is undergoing a paradigm shift from complex ex vivo manufacturing to direct in vivo generation of CAR-T cells. This innovative approach leverages non-viral delivery platforms to reprogram a patient’s own immune cells in situ, promising to overcome critical barriers of cost, scalability, and accessibility. The 2025 American Society of Hematology (ASH) Annual Meeting served as a showcase for groundbreaking preclinical data across a diverse array of non-viral technologies, including advanced lipid nanoparticles (LNPs), virus-like particles (VLPs), and polymeric nanoparticles. This correspondence summarizes the latest reports on these platforms, highlighting their potential to revolutionize the treatment of both autoimmune diseases and hematological malignancies.

Topik & Kata Kunci

Diseases of the blood and blood-forming organs Neoplasms. Tumors. Oncology. Including cancer and carcinogens

Penulis (4)

Bin Xue

Yifan Liu

Aibin Liang

Wenjun Zhang

Format Sitasi

APA MLA BibTeX

Xue, B., Liu, Y., Liang, A., Zhang, W. (2026). Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting. https://doi.org/10.1186/s40164-026-00765-5

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →

Lihat di Sumber doi.org/10.1186/s40164-026-00765-5

Informasi Jurnal

Tahun Terbit: 2026
Sumber Database: DOAJ
DOI: 10.1186/s40164-026-00765-5
Akses: Open Access ✓